Pharming Group  logo
PHARPharming Group
Trade PHAR now
Pharming Group  primary media

About Pharming Group

Pharming Group (EURONEXT:PHARM), (NASDAQ:PHAR) is a biopharmaceutical company engaged in the development, production, and commercialization of innovative treatments for rare diseases and unmet medical needs. Its portfolio focuses on therapies in the fields of hereditary angioedema and Pompe disease, leveraging its expertise in protein replacement therapies. The company is renowned for Ruconest®, its lead product for the treatment of hereditary angioedema. Pharming Group NV is dedicated to enhancing patient care and improving quality of life through continuous research and development. With a commitment to sustainability and ethical practices, Pharming aims to expand its product offering and reach to address the needs of patients globally, striving for excellence in everything they do, with the ultimate goal of becoming a beacon of hope for those facing rare and challenging diseases.

What is PHAR known for?

Snapshot

Public US
Ownership
1988
Year founded
869
Employees
Leiden, Netherlands
Head office
1 of 4
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...

Operations

Produtos e/ou serviços de Pharming Group

  • Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema treatment.
  • Leniolisib, an oral treatment for activated phosphoinositide 3-kinase delta syndrome under investigation.
  • Development of an alpha-glucosidase treatment for Pompe disease.
  • Innovations in gene therapy aimed at providing long-term solutions for genetic disorders.
  • Research in enzyme replacement therapies targeting rare diseases.
  • Collaboration on COVID-19 treatment using recombinant human C1 esterase inhibitor.

equipe executiva do Pharming Group

  • Mr. Fabrice Chouraqui Ph.D., Pharm.D.CEO & Executive Director
  • Mr. Kenneth Lynard EMBAChief Financial Officer
  • Ms. Mireille Sanders M.Sc.Chief Operations Officer
  • Ms. Susanne EmbletonInvestor Relations Manager
  • Mr. Ruud Van OutersterpChief Legal & Compliance Officer
  • Mr. Michael LevitanVP of Investor Relations & Corporate Communications
  • Ms. Ines BernalChief People Officer
  • Dr. Anurag Relan M.D., MPHChief Medical Officer
  • Dr. Alexander Breidenbach M.B.A.Chief Business Officer
  • Ms. Leverne MarshChief Commercial Officer

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.